Table 2.
Characteristics of patients developed brain metastases
| Characteristic | Total (n = 67) | EGFR MT (n = 27) | EGFR WT (n = 40) | p value |
|---|---|---|---|---|
| Sex | 0.014 | |||
| Male | 35 (52.2) | 9 (33.3) | 26 (65.0) | |
| Female | 32 (47.8) | 18 (66.6) | 14 (35.0) | |
| Age, yr | 68 (41–85) | 64 (45–83) | 68 (41–85) | 0.335 |
| ECOG PS | 0.040 | |||
| 0–1 | 56 (83.6) | 26 (96.3) | 30 (75.0) | |
| 2–3 | 11 (16.4) | 1 (3.7) | 10 (25.0) | |
| Smoking history | 0.013 | |||
| Never-smoker | 31 (46.3) | 17 (63.0) | 14 (35.0) | |
| Former smoker | 16 (23.9) | 7 (25.9) | 9 (22.5) | |
| Current smoker | 20 (29.9) | 3 (11.1) | 17 (42.5) | |
| Pathologic histology | 0.085 | |||
| Adenocarcinoma | 47 (70.1) | 23 (85.2) | 24 (60.0) | |
| Squamous | 6 (9.0) | 0 | 6 (15.0) | |
| Large cell | 10 (14.9) | 3 (11.1) | 7 (17.5) | |
| Other | 4 (6.0) | 1 (3.7) | 3 (7.5) | |
| Symptoms of BM | 0.803 | |||
| Absent | 30 (44.8) | 13 (48.1) | 17 (42.5) | |
| Present | 37 (55.2) | 14 (51.9) | 23 (57.5) | |
| EGFR TKI treatment | ||||
| 1st line | 13 (48.1) | |||
| 2nd line | 11 (40.7) | |||
| 3rd line | 2 (7.4) | |||
| None | 1 (3.7) | |||
| Timing of BM | 0.599 | |||
| Synchronous | 47 (70.1) | 20 (74.1) | 27 (67.5) | |
| Metachronous | 20 (29.9) | 7 (25.9) | 13 (32.5) | |
| No. of lesions | 0.741 | |||
| Single | 19 (28.4) | 6 (22.2) | 13 (32.5) | |
| 2–4 | 11 (16.4) | 5 (18.5) | 6 (15.0) | |
| ≥ 5 | 37 (55.2) | 16 (59.3) | 21 (52.5) | |
| Local treatment of BM | 0.896 | |||
| WBRT | 37 (55.2) | 15 (55.6) | 22 (55.0) | |
| SRS | 11 (16.4) | 5 (18.5) | 6 (15.0) | |
| Surgery | 4 (6.0) | 2 (7.4) | 2 (5.0) | |
| None | 15 (22.4) | 5 (18.5) | 10 (25.0) |
Values are presented as number (%) or median (range).
EGFR, epidermal growth factor receptor; MT, mutation type; WT, wild type; ECOG PS, Eastern Cooperative Oncology Group Performance status; BM, brain metastasis; TKI, tyrosine kinase inhibitor; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery.